Research2 sources
Expansion and cytotoxicity of mucosal CAR + T cells in enterocolitis associated with BCMA CAR-T cell therapy
Nature · By Tania P. Sainz ·
The Brief · written from 2 sources
- Two Nature Medicine papers published 19 November 2026 characterise immune effector cell-associated enterocolitis after BCMA-directed CAR T cell therapy.
- One study uses multimodal profiling of biopsy-confirmed cases after ciltacabtagene autoleucel, reporting that CAR T cell infiltrates are concentrated in the gut mucosa.
- A larger multicenter case series reports that only 32% of patients who developed the enterocolitis had achieved disease response.
Why it matters
The studies describe a serious gastrointestinal complication of a widely used cancer immunotherapy, which helps clinicians recognise and characterise it in patients receiving BCMA CAR T cells.
Who’s affected
- clinicians treating multiple myeloma with CAR T cell therapy
- researchers in cell therapy and cancer immunology
- #car t cells
- #bcma
- #enterocolitis
- #immunotherapy
- #multiple myeloma
- #adverse events
Nature Medicine, Published online: 19 November 2026; doi:10.1038/s41591-026-04731-w Multimodal profiling of patients with biopsy-confirmed immune effector cell-associated enterocolitis following ciltacabtagene autoleucel shows that CAR T cell infiltrates are concentrated in the…
Timeline
Full coverage · 2 sources
- 12h ago ↗
nature.com
Expansion and cytotoxicity of mucosal CAR + T cells in enterocolitis associated with BCMA CAR-T cell therapy
- 12h ago ↗
nature.com
Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy